TD Private Client Wealth’s Apogee Therapeutics APGE Stock Holding History

TD Private Client Wealth’s Portfolio APGE Stock Details APGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.39K	Hold	18	–	–	﹤0.01%	1336
2026 Q1	$1.51K	Hold	18	–	–	﹤0.01%	1328
2025 Q4	$1.36K	Hold	18	–	–	﹤0.01%	1324
2025 Q3	$715	Buy	+18	New	+$687	﹤0.01%	1393

Other funds holding APGE

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

TD Private Client Wealth's APGE Position: Q2 2026 in Review

TD Private Client Wealth held its Apogee Therapeutics (APGE) position steady in Q2 2026 at 18 shares worth $2.39K. The position accounts for ﹤0.01% of the portfolio, ranked #1336.

TD Private Client Wealth first reported a position in APGE in Q3 2025 and has held it in 4 quarters since. 288 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

TD Private Client Wealth held 18 shares of Apogee Therapeutics worth $2.39K as of Q2 2026.
TD Private Client Wealth left its Apogee Therapeutics share count unchanged in Q2 2026.
Apogee Therapeutics made up ﹤0.01% of TD Private Client Wealth's portfolio in Q2 2026, its #1336 holding.
TD Private Client Wealth first reported a position in Apogee Therapeutics in Q3 2025 and has held it in 4 quarters since.
288 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on TD Private Client Wealth's 13F filing for Q2 2026, filed 4 Aug 2026.